Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of RTX-240 Monotherapy and in Combination With Pembrolizumab

NCT04372706 is registered in ClinicalTrials.gov with Rubius Therapeutics as lead sponsor.

NCT NCT04372706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04372706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of RTX-240 Monotherapy and in Combination With Pembrolizumab
Lead sponsor
Rubius Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
May 6, 2020
Completion date
November 30, 2022
Enrollment
69 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, aml adult